• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cell of origin alters myeloid-mediated immunosuppression in lung adenocarcinoma.肺癌的起源细胞改变髓系介导的免疫抑制作用。
bioRxiv. 2024 Jun 23:2024.06.19.599651. doi: 10.1101/2024.06.19.599651.
2
Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.肺泡 I 型细胞能够产生 KRAS 诱导的肺腺癌。
Cell Rep. 2023 Dec 26;42(12):113286. doi: 10.1016/j.celrep.2023.113286. Epub 2023 Nov 22.
3
Cross-Species Transcriptome Profiling Identifies New Alveolar Epithelial Type I Cell-Specific Genes.跨物种转录组分析鉴定出新的肺泡I型上皮细胞特异性基因。
Am J Respir Cell Mol Biol. 2017 Mar;56(3):310-321. doi: 10.1165/rcmb.2016-0071OC.
4
p53 governs an AT1 differentiation programme in lung cancer suppression.p53 调控肺癌抑制中的 AT1 分化程序。
Nature. 2023 Jul;619(7971):851-859. doi: 10.1038/s41586-023-06253-8. Epub 2023 Jul 19.
5
GRAMD2 alveolar type I cell plasticity facilitates cell state transitions in organoid culture.GRAMD2肺泡I型细胞可塑性促进类器官培养中的细胞状态转变。
bioRxiv. 2023 Oct 18:2023.10.17.560801. doi: 10.1101/2023.10.17.560801.
6
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.肺泡分化驱动肺腺癌对 KRAS 抑制的耐药性。
Cancer Discov. 2024 Feb 8;14(2):308-325. doi: 10.1158/2159-8290.CD-23-0289.
7
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma.肺泡分化驱动肺腺癌对KRAS抑制的抗性。
bioRxiv. 2023 Oct 1:2023.09.29.560194. doi: 10.1101/2023.09.29.560194.
8
Early-stage lung cancer is driven by a transitional cell state dependent on a KRAS-ITGA3-SRC axis.早期肺癌由依赖于 KRAS-ITGA3-SRC 轴的过渡细胞状态驱动。
EMBO J. 2024 Jul;43(14):2843-2861. doi: 10.1038/s44318-024-00113-5. Epub 2024 May 16.
9
Smoking-induced CCNA2 expression promotes lung adenocarcinoma tumorigenesis by boosting AT2/AT2-like cell differentiation.吸烟诱导的 CCNA2 表达通过促进 AT2/AT2 样细胞分化促进肺腺癌肿瘤发生。
Cancer Lett. 2024 Jun 28;592:216922. doi: 10.1016/j.canlet.2024.216922. Epub 2024 May 3.
10
IRF8 deficiency-induced myeloid-derived suppressor cell promote immune evasion in lung adenocarcinoma.IRF8 缺陷诱导的髓系来源抑制细胞促进肺腺癌中的免疫逃逸。
J Transl Med. 2024 Jul 24;22(1):678. doi: 10.1186/s12967-024-05519-7.

本文引用的文献

1
CellRank 2: unified fate mapping in multiview single-cell data.CellRank 2:多视图单细胞数据中的统一命运映射。
Nat Methods. 2024 Jul;21(7):1196-1205. doi: 10.1038/s41592-024-02303-9. Epub 2024 Jun 13.
2
Single-cell and spatial transcriptomics analysis of non-small cell lung cancer.单细胞和空间转录组学分析非小细胞肺癌。
Nat Commun. 2024 May 23;15(1):4388. doi: 10.1038/s41467-024-48700-8.
3
Tertiary lymphoid structures in cancer: maturation and induction.癌症中的三级淋巴结构:成熟与诱导。
Front Immunol. 2024 Apr 16;15:1369626. doi: 10.3389/fimmu.2024.1369626. eCollection 2024.
4
Blocking the MIF-CD74 axis augments radiotherapy efficacy for brain metastasis in NSCLC via synergistically promoting microglia M1 polarization.阻断 MIF-CD74 轴通过协同促进小胶质细胞 M1 极化增强 NSCLC 脑转移的放疗疗效。
J Exp Clin Cancer Res. 2024 Apr 29;43(1):128. doi: 10.1186/s13046-024-03024-9.
5
Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma.解析以肿瘤相关巨噬细胞为主导的异质性,用于肺腺癌的生存预后评估和免疫治疗反应预测。
Sci Rep. 2024 Apr 23;14(1):9276. doi: 10.1038/s41598-024-60132-4.
6
Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications.癌症中的三级淋巴结构:免疫机制及临床意义
MedComm (2020). 2024 Mar 11;5(3):e489. doi: 10.1002/mco2.489. eCollection 2024 Mar.
7
An atlas of epithelial cell states and plasticity in lung adenocarcinoma.肺腺癌上皮细胞状态和可塑性图谱。
Nature. 2024 Mar;627(8004):656-663. doi: 10.1038/s41586-024-07113-9. Epub 2024 Feb 28.
8
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.恩替诺特、纳武利尤单抗和伊匹单抗治疗晚期 HER2 阴性乳腺癌女性患者:一项 Ib 期临床试验。
Nat Cancer. 2024 Jun;5(6):866-879. doi: 10.1038/s43018-024-00729-w. Epub 2024 Feb 14.
9
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.CD74 与炎症肿瘤免疫微环境相关,并可预测实体瘤患者对 PD-1/CTLA-4 双特异性抗体的反应性。
Cancer Immunol Immunother. 2024 Jan 27;73(2):36. doi: 10.1007/s00262-023-03604-2.
10
Macrophage plasticity and function in cancer and pregnancy.巨噬细胞在癌症与妊娠中的可塑性及功能
Front Immunol. 2024 Jan 11;14:1333549. doi: 10.3389/fimmu.2023.1333549. eCollection 2023.

肺癌的起源细胞改变髓系介导的免疫抑制作用。

Cell of origin alters myeloid-mediated immunosuppression in lung adenocarcinoma.

作者信息

Yang Minxiao, Shulkin Noah, Gonzalez Edgar, Castillo Jonathan, Yan Chunli, Zhang Keqiang, Arvanitis Leonidas, Borok Zea, Wallace W Dean, Raz Dan, Torres Evanthia T Roussos, Marconett Crystal N

机构信息

Department of Integrative Translational Sciences, Beckman Research Institute, City of Hope, Duarte, CA USA 91010.

Department of Surgery, University of Southern California, Los Angeles, CA USA 90089.

出版信息

bioRxiv. 2024 Jun 23:2024.06.19.599651. doi: 10.1101/2024.06.19.599651.

DOI:10.1101/2024.06.19.599651
PMID:38948812
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11213232/
Abstract

Solid carcinomas are often highly heterogenous cancers, arising from multiple epithelial cells of origin. Yet, how the cell of origin influences the response of the tumor microenvironment is poorly understood. Lung adenocarcinoma (LUAD) arises in the distal alveolar epithelium which is populated primarily by alveolar epithelial type I (AT1) and type II (AT2) cells. It has been previously reported that AT1 cells can give rise to a histologically-defined LUAD that is distinct in pathology and transcriptomic identity from that arising from AT2 cells. To determine how cells of origin influence the tumor immune microenvironment (TIME) landscape, we comprehensively characterized transcriptomic, molecular, and cellular states within the TIME of AT1 and AT2-derived LUAD using KRAS oncogenic driver mouse models. Myeloid cells within the AT1-derived LUAD TIME were increased, specifically, immunoreactive monocytes and tumor associated macrophages (TAMs). In contrast, the AT2 LUAD TIME was enriched for Arginase-1 myeloid derived suppressor cells (MDSC) and TAMs expressing profiles suggestive of immunosuppressive function. Validation of immune infiltration was performed using flow cytometry, and intercellular interaction analysis between the cells of origin and major myeloid cell populations indicated that cell-type specific markers SFTPD in AT2 cells and CAV1 in AT1 cells mediated unique interactions with myeloid cells of the differential immunosuppressive states within each cell of origin mouse model. Taken together, AT1-derived LUAD presents with an anti-tumor, immunoreactive TIME, while the TIME of AT2-derived LUAD has hallmarks of immunosuppression. This study suggests that LUAD cell of origin influences the composition and suppression status of the TIME landscape and may hold critical implications for patient response to immunotherapy.

摘要

实体癌通常是高度异质性的癌症,起源于多种上皮细胞。然而,细胞起源如何影响肿瘤微环境的反应仍知之甚少。肺腺癌(LUAD)起源于远端肺泡上皮,主要由I型肺泡上皮细胞(AT1)和II型肺泡上皮细胞(AT2)组成。此前有报道称,AT1细胞可产生一种组织学定义的LUAD,其病理和转录组特征与AT2细胞产生的LUAD不同。为了确定细胞起源如何影响肿瘤免疫微环境(TIME)格局,我们使用KRAS致癌驱动小鼠模型全面表征了AT1和AT2来源的LUAD的TIME内的转录组、分子和细胞状态。AT1来源的LUAD的TIME内的髓系细胞增加,特别是免疫反应性单核细胞和肿瘤相关巨噬细胞(TAM)。相比之下,AT2来源的LUAD的TIME富含精氨酸酶-1髓系来源抑制细胞(MDSC)和表达提示免疫抑制功能的TAM。使用流式细胞术对免疫浸润进行了验证,起源细胞与主要髓系细胞群体之间的细胞间相互作用分析表明,AT2细胞中的细胞类型特异性标志物SFTPD和AT1细胞中的CAV1介导了与每个起源细胞小鼠模型内不同免疫抑制状态的髓系细胞的独特相互作用。综上所述,AT1来源的LUAD呈现抗肿瘤、免疫反应性的TIME,而AT2来源的LUAD的TIME具有免疫抑制特征。这项研究表明,LUAD的细胞起源影响TIME格局的组成和抑制状态,可能对患者对免疫治疗的反应具有关键意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/a87a3cc31496/nihpp-2024.06.19.599651v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/895aed2fb89a/nihpp-2024.06.19.599651v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/e2bab870fc70/nihpp-2024.06.19.599651v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/4e4a363f646a/nihpp-2024.06.19.599651v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/e413a4ce944b/nihpp-2024.06.19.599651v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/a87a3cc31496/nihpp-2024.06.19.599651v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/895aed2fb89a/nihpp-2024.06.19.599651v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/e2bab870fc70/nihpp-2024.06.19.599651v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/4e4a363f646a/nihpp-2024.06.19.599651v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/e413a4ce944b/nihpp-2024.06.19.599651v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3075/11213232/a87a3cc31496/nihpp-2024.06.19.599651v1-f0005.jpg